Contact Information: Contact: Company Contact: Delcath Systems, Inc. Richard L. Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper (212) 838-1444 Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006
Delcath Systems Appoints Eamonn Hobbs to Board of Directors
| Source: Delcath Systems
NEW YORK, NY--(Marketwire - October 15, 2008) - Delcath Systems, Inc. (NASDAQ : DCTH ) today
announced the appointment of Mr. Eamonn Hobbs to Delcath's Board of
Directors. Mr. Hobbs is President and Chief Executive Officer of
AngioDynamics, Inc. (NASDAQ : ANGO ), a leading medical device company
specializing in the development and sales of medical technology serving the
needs of interventional oncologists and vascular interventionalists.
Mr. Hobbs, a Co-Founder of AngioDynamics, built his company into a leading
medical technology company with an international market presence with a
highly diverse product line. Throughout his tenure at AngioDynamics, Mr.
Hobbs has led the Company's efforts in marketing, strategic planning,
product development, and general management. In 2004, AngioDynamics was
spun off from E-Z-EM, Inc., a company focusing on diagnostic radiology and
gastrointestinal technologies, and of which Mr. Hobbs was the Senior
Vice-President since 1988. Before his involvement with these companies,
Mr. Hobbs was the Director of Marketing and Product Development at NAMIC,
Founder, President and CEO of Hobbs Medical, Inc., and a Product
Development Engineer at Cook Incorporated.
On joining Delcath's Board of Directors, Mr. Hobbs commented, "This is an
exciting time for Delcath, and I am pleased to be joining the Board during
this period of growth and expansion. I am impressed with the Company's
technology, the promising results of the Phase III Trial, and the excellent
management team. I believe that the Company is poised for significantly
more growth and success in the emerging market of minimally invasive cancer
treatments, and I look forward to leveraging my extensive experience to aid
that successful growth."
Mr. Hobbs continues to be highly active in the field of interventional
radiology, where he has been named an Honorary Fellow of the Society of
Interventional Radiology ("SIR"), is on the SIR Strategic Planning
Committee, and is a Member of the Society of Cardiovascular and
Interventional Radiology. Mr. Hobbs is a frequent presenter at industry
and medical conferences, and sits on the Board of Directors of the Medical
Device Manufacturers Association, the Society of Interventional Radiology
Foundation, and the American College of Phlebology Foundation.
Commenting on today's announcement, Richard L. Taney, President and Chief
Executive Officer of Delcath, stated, "We are delighted to have Eamonn join
the Board of Directors of Delcath. His successful leadership of
AngioDynamics, his experience within the medical device industry and his
involvement in a number of influential medical organizations make him a
welcome addition to our Board of Directors. I look forward to working with
Mr. Hobbs and the entire Board while we continue our progress in completing
our clinical trials."
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company has developed a proprietary, patented system
which will improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel drug
delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these high
doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The Company's
intellectual property portfolio consists of twenty-eight patents on a
worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.